Business Wire

Tilray Receives License to Produce Medical Cannabis in the European Union

Jaa

Tilray, a global pioneer in medical cannabis research and production, announced plans today to invest up to €20 million in a European Union Campus (EU Campus) after receiving licenses from the Government of Portugal to import cannabis genetics and to cultivate cannabis for medical purposes.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170907005138/en/

BIOCANT Research Park in Cantanhede, Portugal (Photo: Business Wire)

BIOCANT Research Park in Cantanhede, Portugal (Photo: Business Wire)

“Tilray’s EU Campus is another strategic milestone as we aim to build the world’s most trusted and admired medical cannabis brand,” said Brendan Kennedy, Chief Executive Officer of Tilray. “For the past two years we’ve been working hard to find the right location for cultivation, processing, and research facilities to serve rapidly growing demand for high-quality medical cannabis products in Europe. Portugal has the ideal climate to cultivate cannabis, a highly-skilled health care workforce, and a vibrant research community. It’s more environmentally-friendly and cost-effective to supply European patients from Portugal than from northern climates.”

State-of-the-Art EU Campus Will Begin Operations This Year

To establish the EU Campus, Tilray will invest up to €20 million through its affiliate, Tilray Portugal Unipessoal Lda., in multiple facilities located in and around the BIOCANT Research Park in Cantanhede, Portugal. The EU Campus will include indoor, outdoor, and greenhouse cultivation sites, as well as facilities to process, package, and distribute medical cannabis and cannabinoid-derived medical products. As a part of the BIOCANT biotechnology and life sciences research park, the EU Campus will serve as a hub supporting Tilray’s clinical research and product development efforts across Europe.

Tilray is currently leasing laboratory and indoor cultivation space within BIOCANT. This month, Tilray will begin construction on a greenhouse and a processing facility on property purchased by the company. Phase one of the project, which is expected to be complete by spring of 2018, includes an indoor laboratory and genetics bank, outdoor cultivation sites, a 10,000 m2 greenhouse, and a 1,500 m2 processing facility. Subsequent phases, which are expected to be completed by 2020, will add 15,000 m2 of greenhouse cultivation space and another 1,500 m2 for processing. Over the next three years, the project is expected to create 100 direct jobs, including highly-skilled positions.

EU Campus Accelerates Tilray’s Global Expansion Strategy

In response to considerable unmet need for high-quality medical cannabis, Tilray is investing aggressively to expand its operations around the world. In addition to Tilray Portugal Unipessoal Lda., Tilray has wholly-owned subsidiaries in Germany (Tilray Deutschland GmbH), Canada (Tilray Canada Ltd.), and Australia and New Zealand (Tilray Australia and New Zealand Pty. Ltd.).

Tilray has a proven track record as a global pioneer in the medical cannabis industry:

  • In 2014, Tilray was one of the first companies to be federally-licensed to cultivate, process and distribute medical cannabis in Canada.
  • In December 2016, Tilray became the first medical cannabis licensed producer in North America to be GMP-certified in accordance with the European Medicines Agency’s (EMA) Good Manufacturing Practice (GMP) standards. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes. In countries new to medical cannabis, GMP certification provides regulators and health care providers with certainty that Tilray products are a safe and smart choice.
  • In 2016 and 2017, Tilray launched clinical research partnerships with world-leading hospitals and universities to study the safety and efficacy of medical cannabis for a diverse range of conditions, including post-traumatic stress disorder (PTSD), chronic obstructive pulmonary disorder (COPD), pediatric epilepsy, and chemotherapy-induced nausea and vomiting (CINV).
  • Throughout the last year, Tilray became the first company to legally export medical cannabis products from North America to the European Union, Australia, New Zealand, and South America. Tilray products are currently available in six countries spanning four continents.

By the end of 2017, Tilray expects to export medical cannabis products to five more countries. The company also anticipates announcing federal licenses from additional countries, as well as research partnerships in Portugal, Germany, and other countries around the world.

Tilray Portugal Timeline

Tilray executives first visited Portugal in 2015. After conducting extensive due diligence, consultation with stakeholders, and a country-wide property search, Tilray reached a Memorandum of Understanding with the Government of Portugal in October 2016. Tilray Portugal Unipessoal Lda. was incorporated in March 2017. The company purchased property in Cantanhede in July 2017.

About Tilray

Tilray is a global pioneer in the research and production of medical cannabis and cannabinoids. Tilray currently serves tens of thousands of patients, physicians, pharmacies, governments, hospitals, and researchers in six countries spanning four continents through its affiliated entities in Australia and New Zealand (Tilray Australia New Zealand Pty Ltd), Canada (Tilray Canada Ltd), Germany (Tilray Deutschland GmbH), and Portugal (Tilray Portugal Unipessoal Lda).

Contact information

Tilray
Portugal:
TilrayPortugal@brunswickgroup.com
or
Europe:
Tilray@brunswickgroup.com
or
Canada:
Chrissy Roebuck, 1-416-560-5712
chrissy@pomppr.com
or
Global:
Zack Hutson, +1-415-534-5541
zack.hutson@tilray.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Off on Holiday with Mytyres.co.uk – but Safe25.6.2018 12:00Tiedote

Summertime is holiday time. And the car is still the main means of transport that families use to get to their holiday destination. This is why responsible drivers should place great importance on their own safety – and that of their passengers. One of the simplest and most effective measures is to start preparations as early as possible. If you pack, load and leave early enough, you won’t need to race and you’ll arrive relaxed. It’s also helpful to give the vehicle the once over at least one week before departure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005265/en/ The brakes should be in proper working order and the oil, coolant and brake fluid levels should all be checked. The windscreen washer reservoir should also be refilled. When fully loaded, the headlamps must also be adjusted – a good opportunity to consult the manual again. If the total weight of the vehicle increases due to the heavy luggage and sever

Tokenization under the EU Regulations with Smartlands Will Define the Future of Investment Banking25.6.2018 11:00Tiedote

The volatile nature of the cryptocurrency market is the largest threat that keeps a majority of investors away from the industry, and many businesses from wide adoption of blockchain. The Smartlands Platform solves this challenge by creating the necessary legal framework to enforce assets tokenization in full compliance with the law. Smartlands is going to employ a crowdfunding platform license to create a solid foundation for the future of assets tokenization within the platform. In order to be fully compliant with the law, the company plans further expansion by launching a new office in Vilnius. Asset-backed tokens issued on Smartlands, under crowdfunding platform license, will be sold as securities. The tokens will combine the advantages of blockchain technology and classical investment instruments. They will be in compliance with the legislation of the European Union, provide greater protection for investors, and will be a secure tool to attract investments for companies, whilst pr

Lenovo Attains Status as Largest Global Provider of TOP500 Supercomputers25.6.2018 10:01Tiedote

Today, at the International Supercomputing Conference (ISC) in Frankfurt, Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY) continued its global momentum, becoming the world’s largest TOP500 supercomputing provider measured by the number of systems ranked on the TOP500 list. 117 of the 500 most powerful supercomputers included in the TOP500 are Lenovo installations, meaning nearly one out of every four systems (23.4 percent) on the prestigious list is a Lenovo solution. “Last year, we set a goal to become the world’s largest provider of TOP500 computing systems by 2020. We have reached that goal two years ahead of our original plan,” said Kirk Skaugen, President of Lenovo Data Center Group. “This distinction is a testament to our commitment to prioritize customer satisfaction, deliver cutting edge innovation and performance and be the world’s most trusted data center partner. We are motivated every day by the scientists and their groundbreaking research as we work together to solve hum

Enterprise DevOps for the Cloud25.6.2018 10:00Tiedote

XebiaLabs, the recognized leader in enterprise DevOps and Continuous Delivery software, today announced a DevOps framework that provides a smooth pathway to the cloud for companies who are moving applications to cloud-based resources on a large scale. The framework connects enterprise DevOps practices with common cloud management functionality and provides an essential foundation as enterprises accelerate their transformations to cloud-based applications. Cloud Does Not Equal DevOps Easy access to public cloud technologies creates a common misconception: moving to the cloud will not only provide more flexible and scalable infrastructure at a lower cost, but it will also accelerate the delivery of applications to the customer. In reality, moving to the cloud is just one step in that journey. Enterprises that are looking to improve and accelerate software delivery are implementing DevOps practices that span the entire software delivery value stream. These practices are generally unrelate

XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 201825.6.2018 10:00Tiedote

XebiaLabs, the recognized leader in Enterprise DevOps and Continuous Delivery software, today announced the release of The Periodic Table of DevOps Tools v.3, an update of its free, industry-recognized DevOps landscape tool. The latest release of this acclaimed tool features 52 new DevOps tools, a new design, and the addition of categories, such as Analytics and AIOps, to reflect the expanding DevOps tools and technologies market. In addition, users can select a tool in the Periodic Table and immediately visualize it in the software delivery pipeline using XebiaLabs’ integrated DevOps Diagram Generator. DevOps pipeline diagrams can be easily customized, downloaded, printed, and shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005106/en/ XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 2018 (Graphic: Business Wire) Given the fast pace at which new DevOps tools become availa

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme